Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study - Archive ouverte HAL Access content directly
Journal Articles Targeted Oncology Year : 2021

Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study

, (1) , (2) , (3) , , (4) , (5) , (6) , (7) , (8) , (9, 10) , (11) , (9, 10)
1
2
3
4
5
6
7
8
9
10
11
Not file

Dates and versions

hal-03623633 , version 1 (29-03-2022)

Identifiers

Cite

Almudena Callejo, Sara Faouzi, Olivier Bouché, F. Bertucci, Thomas Chevalier, et al.. Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study. Targeted Oncology, 2021, 16 (4), pp.485-492. ⟨10.1007/s11523-021-00820-7⟩. ⟨hal-03623633⟩
9 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More